Compare NSP & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSP | RLMD |
|---|---|---|
| Founded | 1986 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 819.5M | 784.6M |
| IPO Year | 1996 | 2012 |
| Metric | NSP | RLMD |
|---|---|---|
| Price | $31.73 | $7.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $47.67 | $12.40 |
| AVG Volume (30 Days) | 816.6K | ★ 1.4M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 8.30% | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,812,000,000.00 | $13,070.00 |
| Revenue This Year | $3.45 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.51 | ★ 154.83 |
| 52 Week Low | $18.57 | $0.27 |
| 52 Week High | $80.45 | $7.94 |
| Indicator | NSP | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 61.67 |
| Support Level | $31.00 | $3.49 |
| Resistance Level | $39.86 | $7.41 |
| Average True Range (ATR) | 1.75 | 0.45 |
| MACD | 0.47 | -0.04 |
| Stochastic Oscillator | 96.55 | 65.50 |
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.